Mettler-Toledo International Inc. Q2 FY2025 earnings call

Management Statement and Operational Highlights:

• Performance: Pleased with second quarter results, growth in most businesses despite challenging conditions; team performed well, benefited from innovative product portfolio and strategic programs.
• Tariffs: U.S. administration's tariff increase on Switzerland negatively impacts EPS guidance; mitigation actions ongoing to offset tariffs next year.
• Geopolitical and Market Conditions: Cautious customer investments due to trade disputes and policy uncertainties, but well-positioned to benefit from future investments.
• Business Segments: Lab had mixed market conditions; Americas had stronger growth; Europe was flat; Asia/Rest of the World had better-than-expected results with growth in Southeast Asia but softness in China; service growth initiative making progress.
• Growth Opportunities: Onshoring and regional supply chain development, replacement of aging equipment, biopharma and life sciences investments, and automation/digitalization trends.

Segment Performance:

• Laboratory: Grew slightly in the quarter; good growth from pharma and biopharma customers offset by softer demand from academia, biotech, and chemical sectors; bioprocessing-related sales remain strong.
• Industrial: Core industrial up 2% and product inspection up 8% in the quarter; had growth in core industrial despite challenging conditions, capitalizing on automation and productivity solutions.
• Food Retail: Flat in the quarter.
• Service: Grew 4% in the quarter and 5% year-to-date, impacted a bit by timing issues but optimistic for growth in the second half. Revenue contributions: Life sciences overall represents about 40% of revenue, with around 2/3 supporting production and QA/QC operations; approximately half of global sales support production processes in various applications.

Guidance:

• Third Quarter 2025: Local currency sales growth 3%-4%, operating margin decrease ~130 basis points, adjusted EPS $10.55-$10.75 (3%-5% growth), including ~5% gross headwind from tariffs.
• Full Year 2025: Local currency sales growth 1%-2% (excluding shipping delays), operating margin down modestly, Swiss tariff increase of 39% negatively impacts full year EPS by ~$0.40, reducing EPS range to $41.70-$42.20.
• Shipping Delays: Impacted Q4 2023 and Q1 2024, reducing 2025 sales growth by 1.5%, operating margin by ~60 basis points, and adjusted EPS by ~4%.

Risks:

• Tariffs: Dynamic tariff environment, especially U.S. tariffs on Switzerland, which negatively impact EPS; uncertainty around new tariffs or retaliatory measures.
• Geopolitical Uncertainties: Impact on customer investments and market conditions.
• Shipping Delays: Historical impact on sales, growth, and margins, though mostly recovered.

Question and Answer: Q: Dan Arias on EPS guide and China demand A: Shawn Vadala and Patrick Kaltenbach discuss EPS impact of Swiss tariffs and China demand stability.

Q: Dan Leonard on product inspection strength A: Patrick Kaltenbach talks about product portfolio expansion and mid-single digit growth forecast.

Q: Patrick Donnelly on segment confidence A: Shawn Vadala discusses lab, industrial, product inspection, and retail segments' growth expectations.

Q: Vijay Kumar on EPS and tax rate A: Shawn Vadala talks about tariff mitigation for 2026 and tax rate expectations.

Q: Jack Meehan on pull-forward and service timing A: Patrick Kaltenbach addresses no pull-forward and service timing issues.

Q: Casey Woodring on onshoring timing A: Patrick Kaltenbach mentions early innings of onshoring impact.

Q: Luke Sergott on replacement cycle A: Shawn Vadala and Patrick Kaltenbach discuss pent-up demand and replacement cycle dynamics.

Q: Tycho Peterson on biopharma R&D A: Patrick Kaltenbach talks about biopharma exposure and manufacturing build-outs.

Q: Michael Ryskin on tariff mitigation A: Shawn Vadala discusses mitigation efforts and supply chain agility.

Q: Josh Waldman on tariff variables and demand visibility A: Shawn Vadala and Patrick Kaltenbach talk about tariff impact variables and demand visibility.

Q: Doug Schenkel on Europe and China demand A: Shawn Vadala and Patrick Kaltenbach discuss Europe's growth outlook and China's stability